Cargando…

Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice

OBJECTIVE: Treatment with glucagon receptor antagonists (GRAs) reduces blood glucose but causes dyslipidemia and accumulation of fat in the liver. We investigated the acute and chronic effects of glucagon on lipid metabolism in mice. METHODS: Chronic effects of glucagon receptor signaling on lipid m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galsgaard, Katrine D., Elmelund, Emilie, Johansen, Christian D., Bomholt, Anna B., Kizilkaya, Hüsün S., Ceutz, Frederik, Hunt, Jenna E., Kissow, Hannelouise, Winther-Sørensen, Marie, Sørensen, Charlotte M., Kruse, Thomas, Lau, Jesper F., Rosenkilde, Mette M., Ørskov, Cathrine, Christoffersen, Christina, Holst, Jens J., Wewer Albrechtsen, Nicolai J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706156/ https://www.ncbi.nlm.nih.gov/pubmed/36400402 http://dx.doi.org/10.1016/j.molmet.2022.101639

Ejemplares similares

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells
por: Elmelund, Emilie, et al.
Publicado: (2022)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism
por: Kjeldsen, Sasha A S, et al.
Publicado: (2021)

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion
por: Douglas Galsgaard, Katrine, et al.
Publicado: (2023)

Intestinal Growth in Glucagon Receptor Knockout Mice Is Not Associated With the Formation of AOM/DSS-Induced Tumors
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Molecular and in vivo phenotyping of missense variants of the human glucagon receptor
por: van der Velden, Wijnand J.C., et al.
Publicado: (2021)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis
por: Winther-Sørensen, Marie, et al.
Publicado: (2020)

Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease
por: Balk-Møller, Emilie, et al.
Publicado: (2019)

The Liver–α-Cell Axis in Health and in Disease
por: Richter, Michael M., et al.
Publicado: (2022)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
por: Ronn, Jonas, et al.
Publicado: (2017)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation
por: Ebbesen, Maria, et al.
Publicado: (2021)

Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R–dependent manner
por: Jepsen, Sara L., et al.
Publicado: (2021)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice
por: Hytting-Andreasen, Rasmus, et al.
Publicado: (2018)

The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease
por: Galsgaard, Katrine D.
Publicado: (2020)

Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation
por: Larger, Etienne, et al.
Publicado: (2016)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor
por: Hennen, Stephanie, et al.
Publicado: (2016)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Intestinal Adaptation upon Chemotherapy-Induced Intestinal Injury in Mice Depends on GLP-2 Receptor Activation
por: Billeschou, Anna, et al.
Publicado: (2021)

Acute administration of interleukin‐6 does not increase secretion of glucagon‐like peptide‐1 in mice
por: Christiansen, Charlotte B., et al.
Publicado: (2018)

Glucagon and Its Receptors in the Mammalian Heart
por: Neumann, Joachim, et al.
Publicado: (2023)

Tail engagement of arrestin at the glucagon receptor
por: Chen, Kun, et al.
Publicado: (2023)

Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes
por: Kizilkaya, Hüsün Sheyma, et al.
Publicado: (2021)

Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2014)

Disruption of the glucagon receptor increases glucagon expression beyond α-cell hyperplasia in zebrafish
por: Kang, Qi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8d3b9d1j60j5f62s8utd05o1fs